Syndromic testing for upper respiratory infections using multiplex RT-PCR
The FTD™ Respiratory pathogens 21 assay1 is a qualitative in vitro nucleic acid amplification test for the detection and differentiation of specific viral and bacterial nucleic acids in nasopharyngeal swab specimens of human origin.
The test is intended as an aid in the diagnosis of respiratory infections caused by influenza A virus (IAV), influenza A virus H1N1 swine-lineage (IAV [H1N1] swl), influenza B virus (IBV), human rhinovirus (HRV), human coronaviruses (HCoV) 229E, NL63, HKU1, and OC43, human parainfluenza viruses (HPIV) 1 through 4, human metapneumoviruses (HMPV) A and B, human bocavirus (HBoV), Mycoplasma pneumoniae (M. pneumoniae), human respiratory syncytial viruses (HRSV) A and B, human parechovirus (HPeV), enterovirus (EV), and human adenovirus (HAdV).
Acute respiratory pathogen infections are common causes of acute local and systemic disease with substantial morbidity and mortality in pediatric, adult, and immunocompromised patients. Early and accurate diagnosis of respiratory pathogens diminishes transmission and complications. More efficient laboratory testing enables the physician to determine appropriate and timely patient treatment.2,3
Features & Benefits
Provides simultaneous detection of probable pathogens with one kit using a single sample for increased testing efficiency.
Syndromic assay enables testing of multiple pathogens at the same time, saving time and resources.4
Supports management of respiratory infections throughout the year as well as during seasonal peaks using the same protocol and solution.
Cost effective and easy to implement in any molecular laboratory.
influenza A influenza A H1N1 swine-lineage influenza B